Advertisement

Möglichkeiten der Androgensuppression und Entwicklung der Androgenresistenz beim Prostatakarzinom

  • H. Schulze

Zusammenfassung

Das Prostatakarzinom ist die zweit- bzw. dritthäufigste Krebstodesursache aller Männer in den westlichen Industriestaaten (Silverberg 1982). In der Bundesrepublik Deutschland sterben jährlich über 9000 Männer an den Folgen dieses Tumors. Für Männer älter als 60 Jahre ist das Prostatakarzinom sogar die führende Krebstodesursache. Neben dieser hohen Mortalitätsrate weist das Prostatakarzinom auch eine hohe jährliche Inzidenzrate auf. In den USA beispielsweise macht das Prostatakarzinom 17 % aller jährlich neu entdeckten Krebserkrankungen bei Männern aus (Silverberg 1982). Umgerechnet auf die derzeitige Lebenserwartung bedeutet dies, daß jeder 20. weiße Amerikaner ein klinisch manifestes Prostatakarzinom entwickeln wird (Seidmann et al. 1978). Weniger als 1% aller klinisch manifesten Prostatakarzinome werden bei Männern unter 50 Jahre diagnostiziert. Die Inzidenz dieses Malignoms steigt dann aber mit zunehmendem Lebensalter rapide und schneller an als die jeder anderen Krebsform. Aus diesen epidemiologischen Daten ergibt sich, daß mit der allgemein zunehmenden Lebenserwartung die Inzidenz des klinisch manifesten Prostatakarzinoms weiter ansteigen wird, wie sie auch in den letzten 50 Jahren ständig angestiegen ist (Devesa u. Silvermann 1978). Hieraus leiten sich statistische Analysen ab, nach denen das Prostatakarzinom innerhalb der nächsten 20 bis 25 Jahren die häufigste Krebstodesursache aller Männer sein wird.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adler A, Burger H, Davis J, Dulmanis A, Hudson B, Sarfaty G, Straffon W (1968) Carcinoma pf prostate: response of plasma luteinizing hormone and testosterone to oestrogen therapy. Br Med J 1: 28CrossRefGoogle Scholar
  2. Adlercreutz H, Rannikko S, Kairento AL, Karonen SL (1981) Hormonal pattern in prostatic cancer. II. Correlation with primary response to endocrine treatment. Acta Endocrinol 98Google Scholar
  3. van Aubel OGJM, Bolt-de Vries J, Blankenstein MA, Schröder FH (1988) Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer. Prostate 12: 191CrossRefGoogle Scholar
  4. Bailar JC, Byar DP, Veterans Administration Cooperative Urological Research Group (1970) Estrogen treatment for cancer of the prostate. Cancer 26: 257PubMedCrossRefGoogle Scholar
  5. Barrack ER, Bujnovsky P, Walsh PC (1983) Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: Characterization of nuclear salt-resistant receptors. Cancer Res 43: 1107PubMedGoogle Scholar
  6. Barrack ER, Brendler CB, Walsh PC (1987) Steroid receptor and biochemical profiles in prostatic cancer: correlation with response to hormonal treatment. Prostate cancer, part A. Research, endocrine treatment, and histopathology. Prog Clin Biol Res 243: 79Google Scholar
  7. Beck PH, McAnnich JW, Goebel JL, Stutzman RE (1978) Plasma testosterone in patients receiving diethylstilbestrol. Urology 11: 157PubMedCrossRefGoogle Scholar
  8. Benson RC, Gorman PA, O’Brien PC, Holicky EL, Veneziale CM (1987) Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 59: 1599PubMedCrossRefGoogle Scholar
  9. Blackard CE, Byar DP, Jordan WP, Veterans Administration Cooperative Urological Research Group (1973) Orchiectomy for advanced prostatic carcinoma: a reevaluation. Urology 1: 553PubMedCrossRefGoogle Scholar
  10. Blankenstein MA, Bolt-de Vries J, Foekens JA (1982) Nuclear androgen receptor assay in biopsy-size specimens of human prostatic tissue. Prostate 3: 351PubMedCrossRefGoogle Scholar
  11. Brendler CB, Isaacs JT, Follansbee AL, Walsh PC (1984) The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. J Urol 131: 694PubMedGoogle Scholar
  12. Brendler CB, Isaacs JT, Walsh PC (1984) An update on the use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate. Proceedings of the Annual Meeting of the American Urological Association, 1984, p 368Google Scholar
  13. Byar DP, Mostofi FK (1972) Carcinoma of the prostate: prognostic evaluation of certain pathological features in 208 radical prostatectomies, examined by the step section technique. Cancer 30: 5PubMedCrossRefGoogle Scholar
  14. Catalona WJ, Scott WW (1986) Carcinoma of the prostate. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA (eds) Campbell’s urology, 5th ed, Saunders, Philadelphia, pp 1463–1534Google Scholar
  15. Chang C, Whelan CT, Popovich TC, Kokontis J, Liao S (1988) Fusion proteins containing androgen receptor sequences and their use in the production of poly-and monoclonal anti-androgen receptor antibodies. Endocrinology 125: 1097CrossRefGoogle Scholar
  16. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419PubMedCrossRefGoogle Scholar
  17. Demuth F (1925) Über Phosphatstoffwechsel. I. Über Hexosephosphatasen in menschlichen Organen und Körperflüssigkeiten. Biochem Z 159: 415Google Scholar
  18. Devesa S, Silverman DT (1978) Cancer incidence and morbidity trends in the United States: 1935-1974. J Natl Cancer Inst 60: 545PubMedGoogle Scholar
  19. Dunning WF (1963) Prostate cancer in the rat. Natl Cancer Inst Monogr 12: 351PubMedGoogle Scholar
  20. Durham SK, Dietze AE (1986) Prostatic adenocarcinoma with and without metastasis to bone in dogs. J Am Vet Assoc 12: 1432Google Scholar
  21. Farnsworth W, Gonder MJ (1977) Prolactin and prostate cancer. Urology 10: 33PubMedCrossRefGoogle Scholar
  22. Faure N, Lemay A, Laroche B, Robert G, Plante R, Jean C, Thabet M, Roy R, Fazekas ATA (1983) Preliminary results on the clinical efficacy and safety of androgen inhibition by an LH-RH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoms. Prostate 4: 601PubMedCrossRefGoogle Scholar
  23. Ginsburg J, O’Reilly B (1983) Climacteric flushing in a man. Br Med J 287: 262CrossRefGoogle Scholar
  24. Giuliani L, Pescatore D, Giberti C, Martorana G, Natta G (1980) Treatment of advanced prostatic carcinoma with Cyproterone acetate and orchiectomy. 5 Year follow-up. Eur Urol 6: 145Google Scholar
  25. Glashan RW, Robinson MRG (1981) Cardiovascular complications in the treatment of prostatic carcinoma. Br J Urol 53: 624PubMedCrossRefGoogle Scholar
  26. Goldie GH, Coldman AJ (1979) A mathematical model formulating the drug sensitivity of tumors to their spontaneous metastatic rate. Cancer Treat Rep 63: 1727PubMedGoogle Scholar
  27. Gutman EB, Sproul EE, Gutman AB (1936) Significance of increased phoshatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 28: 485Google Scholar
  28. Haapiainnen R, Rannikko S, Alfthan O, Adlercreutz H, The Finnprostate Group (1988) Pretreatment plasma levels of testosterone and sex hormone binding globulin binding capacity in relation to clinical staging and survival in prostatic cancer patients. Prostate 12: 325CrossRefGoogle Scholar
  29. Habenicht UF, Witthaus E, Neumann F (1986) Antiandrogene und LH-RH-Agonisten; Endokrinologie in der Initialphase ihrer Anwendung. Akt Urol 17: 10–16CrossRefGoogle Scholar
  30. Hakannson L, Troupe C (1974) On the presence within tumors of clones that differ in sensitivity to cytostatic drugs. Acta Pathol. Microbiol Scand [A] 82: 32Google Scholar
  31. Harper ME, Pierrepoint CG, Griffiths K (1984) Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 20: 477PubMedCrossRefGoogle Scholar
  32. Hayashi T, Taki Y, Ikai K, Hiura M, Kiriyama T, Shizuki K (1987) Latent and clinically manifest prostatic carcinoma. Prostate 10: 275PubMedCrossRefGoogle Scholar
  33. Henriksson P, Johansson SE (1987) Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen. Am J Epidemiol 125: 970–978PubMedGoogle Scholar
  34. Huggins C, Clark PJ (1940) Quantitative studies of prostatic secretion. II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostatic glands of dogs. J Exp Med 72: 747PubMedCrossRefGoogle Scholar
  35. Huggins C, Hodges CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293Google Scholar
  36. Huggins C, Stevens RE, Hodges CV (1941a) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209CrossRefGoogle Scholar
  37. Huggins C, Scott WW, Hodges CV (1941b) Studies on prostatic cancer. HI. The effects of fever, desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 46: 997Google Scholar
  38. Isaacs JT, Heston WDW, Weissman RM, Coffey DS (1978) Animal models of the hormone-sensitive and-insensitive prostatic adenocarcinomas: Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 38: 4353PubMedGoogle Scholar
  39. Isaacs JT, Coffey DS (1981 Adaptation vs. selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070PubMedGoogle Scholar
  40. Isaacs JT (1982) Hormonally responsive versus unresponsive progression of prostatic cancer to antiandfogen therapy as studied with the Dunning R-3327-AT and-G rat adenocarcinomas. Cancer Res 42: 5010PubMedGoogle Scholar
  41. Isaacs JT, Wake N, Coffey DS, Sandberg AA (1982) Genetic instability coupled to clonal selection as a mechanism for tumor progession in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42: 2353–2361PubMedGoogle Scholar
  42. Isaacs JT (1982) Cellular factors in the development of resistance to hormonal therapy. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I CRC Boca Raton, FL, pp 139–156Google Scholar
  43. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1PubMedCrossRefGoogle Scholar
  44. Isaacs JT (1986) Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In: Proceedings of the 2nd NIADDK Symposium on Benign Prostatic Hyperplasia, 1986Google Scholar
  45. Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261PubMedCrossRefGoogle Scholar
  46. Isaacs JT, Hukku B (1988) Nonrandom involvement of Chromosome 4 in the progression of rat prostatic cancer. Prostate 13: 165PubMedCrossRefGoogle Scholar
  47. Jacobi GH, Altwein JE (1978) Bromocriptin, ein neues therapeutisches Prinzip beim Prostata-Adenom und-Karzinom. Dtsch Med Wochenschr 103: 827Google Scholar
  48. Jesik CJ, Holland JM, Lee C (1982) An anatomic and histologic study of the rat prostate. Prostate 3: 81PubMedCrossRefGoogle Scholar
  49. Kahan A, Delrieu F, Amor B, Chiche R, Steg A (1984) Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer. Lancet i: 971CrossRefGoogle Scholar
  50. Kastendieck H (1980) Correlation between atypical primary hyperplasia and carcinoma of the prostate. Hitstologic studies on 180 total prostatectomies due to manifest carcinoma. Pathol Res Pract 169: 366PubMedCrossRefGoogle Scholar
  51. Klijn JGM, de Voogt HJ, Schröder FH, de Jong FH (1985) Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma. Lancet i: 493Google Scholar
  52. Kuhn J-M, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis J-F, Costa P, Husson J-M, Dahan R, Bertagna C, Edelstein R (1989) Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (Buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (Nilutamide). N Engl J Med 321: 413–418PubMedCrossRefGoogle Scholar
  53. Kutscher W, Wolbergs H (1935) prostata Phosphatase. Phys. Chem 236: 237Google Scholar
  54. Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: Devita VT, Hellman S, Rosenberg S (eds) Important advances in oncology Lippincott, Philadelphia, pp 193–217Google Scholar
  55. Labrie F, Dupont A, Belanger A, Emond J, Monfette G (1987) Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer. J Drug Dev 1 [Suppl] 1: 34Google Scholar
  56. Labrie F, Dupont A, Belanger A, Lachance R (1987) Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 138: 804–806PubMedGoogle Scholar
  57. Leav I, Ling GV (1968) Adenocarcinoma of the canine prostate. Cancer 22: 1329PubMedCrossRefGoogle Scholar
  58. Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128: 335PubMedGoogle Scholar
  59. Lesser B, Bruchovsky N (1973) The effects of testosterone, 5α-dihydrotestosterone, and adenosine 3′,5′-monophosphate on cell proliferation and differentiation in rat prostate. Biochim Biophys Acta 308: 426PubMedGoogle Scholar
  60. Ling V (1982) Genetic basis of drug resistance in mammalian cells. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I, CRC, Boca Raton, FL, pp 1–19Google Scholar
  61. Lubahn DB, Joseph DP, Sar M, Tan J, Higgs HN, Larson RE, French FS, Wilson EM (1988) The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression. Mol Endocrinol 2: 1265PubMedCrossRefGoogle Scholar
  62. Lund F, Rasmussen F (1988) Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol 61: 140PubMedCrossRefGoogle Scholar
  63. Mackler MA, Liberti JP, Smith MJV, Koonth WW, Prout GR (1972) The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate. Invest Urol 9: 423PubMedGoogle Scholar
  64. McNeal JE (1983) Monographs in urology, vol. 4. Stamey TA (ed) Custom Publ. Services, pp 3-33Google Scholar
  65. Menon M, Walsh PC (1979) Hormonal therapy for prostatic cancer. In: Murphy GP (ed) Prostatic cancer PSG, Littleton, MA, pp 175-200Google Scholar
  66. Mostofi FK, Sesterhenn J (1981) The role of prostatic acid phosphatase in histological diagnosis of carcinoma of the prostate. Proceedings of the Seventy-Sixth Annual Meeting of the American Urological Association, Abstract 42, 1981Google Scholar
  67. Murphy GP, Beckley S, Brady MF, Chu TM, de Kernion JB, Dhabuwala Ch et al. (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264–1271PubMedCrossRefGoogle Scholar
  68. Nelson WG, Pienta KJ, Barrack ER, Coffey DS (1986) The role of the nuclear matrix in the organization and function of DNA. Ann Rev Biophys Biophys Chem 15: 457CrossRefGoogle Scholar
  69. Oesterling JE, Epstein JI, Walsh PC (1986) The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol 136: 1030PubMedGoogle Scholar
  70. Pollard M (1980) The Pollard tumors. In: Murphy GP (ed) Models for prostate cancer. Liss, New York, pp 293–302Google Scholar
  71. Prout GR, Irwin RJ, Kliman B, Daly JJ, MacLaughlin RA, Griffin PP (1975) Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis. J Urol 113: 834PubMedGoogle Scholar
  72. Prout GR, Kliman B, Daly JJ, McLaughlin RA, Griffin PP, Young HH (1976) II: Endocrine changes after diethylstilbestrol therapy: Effects on prostatic neoplasm and pituitarygonadal axis. Urology 7: 148PubMedCrossRefGoogle Scholar
  73. Radlmaier A, Bormacher K, Neumann F (1989) Hitzewallungen bei Endokrintherapie des Prostatakarzinoms: Modellvorstellung zu ihrer Genese. Akt Urol 20: 143CrossRefGoogle Scholar
  74. Rivenson A, Silverman J (1979) The prostatic carcinoma in laboratory animals. Invest Urol 16: 468PubMedGoogle Scholar
  75. Robinson MRG, Thomas BS (1971) Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 4: 391PubMedCrossRefGoogle Scholar
  76. Sadi MV, Walsh PC, Barrack ER (1990) Can immunocytochemical assay of androgen receptors (AR) predict androgen responsiveness of metastatic prostate cancer? J Urol 143: 204A, Abstract 63Google Scholar
  77. Sandford NL, Searle JW, Kerr JFR (1984) Successive waves of apoptosis in the rat prostate after regulated withdrawal of testosterone stimulation. Pathology 16: 406PubMedCrossRefGoogle Scholar
  78. Schroeder FH, Klijn JG, de Jong FH (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 137: 912PubMedGoogle Scholar
  79. Schulze H, Isaacs JT, Coffey DS (1987) A critical review of the concept of total androgen ablation in the treatment of prostate cancer. In: Murphy GP et al. (eds) Prostate cancer, PT, a progress in clinical and biological research, vol 243 Liss, New York pp 1–19Google Scholar
  80. Schulze H, Kaldenhoff H, Senge T, Westfälische Prostatakarzinom Study Group (1988) Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer. Urol Int 43: 193PubMedCrossRefGoogle Scholar
  81. Schulze H, Segnge T (1990) Influence of different types of antiandrogens on LHRH analog induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 144: 934PubMedGoogle Scholar
  82. Scott WW, Menon M, Walsh PC (1990) Hormonal therapy of prostatic cancer. Cancer 45: 1929Google Scholar
  83. Seidman H, Silverberg F, Boddon A (1978) Probabilities of eventually developing and dying of cancer (risk among persons previously undiagnosed with cancer). Ca-Cancer J Clin 28: 33PubMedCrossRefGoogle Scholar
  84. Shain S, McCullough B, Segaloff A (1975) Spontaneous adenocarcinoma of the ventral prostate of the aged A X C rats. J Natl Cancer Inst 55: 177PubMedGoogle Scholar
  85. Shain SA, McCullough B, Nitchuk M, Boesel RW (1977) Prostatic carcinogenesis in the AXC rat. Oncology 34: 114PubMedCrossRefGoogle Scholar
  86. Shearer RJ, Hendry WF, Sommerville IF, Ferguson JD (1973) Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668PubMedCrossRefGoogle Scholar
  87. Shek LL, Godolphin W (1987) Survival with breast cancer: the importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 25: 243CrossRefGoogle Scholar
  88. Silverberg F (1982) Cancer statistics. Ca (New York) 32: 15Google Scholar
  89. Sinha AA, Blackard CE, Seal US (1977) A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer 40: 2836PubMedCrossRefGoogle Scholar
  90. Skipper HE, Schabel FM, Lyoyd MM (1978) Selection and overgrowth of specifically and permanently drug-resistant tumor cells. Exp Ther Kinetics 15: 207Google Scholar
  91. Smolev JK, Heston WD, Scott WW, Coffey DS (1977) Characterization of the Dunning R-3327-H prostatic adenocarcinoma. An appropriate animal model for prostatic cancer. Cancer Treat Rep 61: 273PubMedGoogle Scholar
  92. The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 311: 1281CrossRefGoogle Scholar
  93. Trachtenberg J, Bujnovsky P, Walsh PC (1982) Androgen receptor content of normal and hyperplastic human prostate. J Clin Endocrinol Metab 54: 17PubMedCrossRefGoogle Scholar
  94. Veterans Administration Cooperative Urological Research Group (VACURG) (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011Google Scholar
  95. Viola MV, Fromowitzh F, Oravez MS, Deb S, Finket G, Lundy J, Harel P, Thor A, Schlom J (1986) Expression of ras oncogene p21 in prostatic cancer. N Engl J Med 314: 133PubMedCrossRefGoogle Scholar
  96. Voigt W, Dunning WF (1974) In vivo metabolism of testosterone-3H in R-3327, an androgen-sensitive rat prostatic adenocarcinoma. Cancer Res 34: 1447PubMedGoogle Scholar
  97. Voigt W, Feldman M, Dunning WF (1975) 5α-Dihydrotestosterone binding proteins and androgen sensitivity in prostatic cancers of Copenhagen rats. Cancer Res 35: 1840PubMedGoogle Scholar
  98. Wake N, Isaacs JT, Sandberg AA (1982) Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42:4131PubMedGoogle Scholar
  99. Walsh PC (1975) Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2: 125PubMedGoogle Scholar
  100. Walsh PC, Siiteri PK (1975) Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J Urol 114: 254PubMedGoogle Scholar
  101. Ward JM, Reznik G, Stinson SF, Lattatuda CP, Longfellow DG, Cameron TP (1980) Histogenesis and morphology of naturally occuring prostatic carcinoma in the ACI/ segHapBR rat. Lab Invest 43: 517PubMedGoogle Scholar
  102. Ware JL (1987) Prostate tumor progression and metastasis. Biochem Biophys Acta 907: 279PubMedGoogle Scholar
  103. Winfield H, Trachtenberg J (1984) A comparison of a powerful luteinising hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer. J Urol 131: 1108Google Scholar
  104. Young HH, Kent JR (1968) Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J Urol 99: 788PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • H. Schulze

There are no affiliations available

Personalised recommendations